Press and News

Babson introduces BetterWay™ blood testing, which uses a pea-sized amount of blood collected from a finger to produce results equivalent to traditional blood testing. BetterWay will first be available at select H-E-B pharmacies, Peoples Rx and Lake Hills Pharmacy in Austin and San Antonio.

 Austin-based health care technology startup Babson Diagnostics announced Thursday that it will launch its blood testing system BetterWay at select Austin H-E-B pharmacies, Peoples Rx and Lake Hills Pharmacy starting in July.

After Austin, Babson plans to launch in San Antonio, Houston and Dallas

Theranos had a lot of bad ideas, but making blood draws smaller and easier wasn’t necessarily one of them. A decade after the now-defunct blood-testing startup emerged from stealth, BD has now claimed an FDA clearance for fingerstick collection hardware that aims to bring the most common blood tests to pharmacies, grocery stores and other retail locations.

Babson strategic partner BD (Becton, Dickinson and Company®) receives FDA 510(k) clearances for BD MiniDraw™ Capillary Blood Collection System. BD MiniDraw™ is a key component of Babson’s BetterWay™ blood testing, a first-of-its-kind offering that combines the convenience of capillary blood collection with the quality of laboratory testing

Today’s clinical laboratory looks more and more like a manufacturing line and less and less like a scientist’s bench. However, the upstream processes of sample collection and preparation have remained largely unchanged over the same period, and in fact haven’t changed much for the past 70 years.

David Stein tells a familiar story. His start-up has invented a device that, with blood from a single finger prick, can run dozens of blood tests and free millions of people from their terror of needles. The $50 billion medical diagnostics business, and, by extension, healthcare itself, is set to be revolutionised.

In today’s rapidly changing health care landscape, clinicians are under increasing pressure to improve health outcomes and to enhance the patient experience. It’s a daunting challenge for medical practices in the face of endless administrative burdens and a growing shortage of health care workers. Patients today expect a modern experience that easily assimilates into their digital lives and meets their increasing focus on health and wellness. They are also notorious for skipping needed testing and not following up on care when it’s inconvenient.

Babson Diagnostics Inc. has line of sight for the commercial launch of its Betterway blood testing ecosystem, which is a less invasive way of taking blood and requires only one-tenth of the sample volume of venipuncture without sacrificing quality or accuracy.

Blood draws do not need to be unpleasant.

Babson CEO David Stein drops by the Let's Talk Medtech studio with an update on the company's progress to reimagine diagnostic blood testing.

We're adding key clinical expertise as we move closer to commercialization of our next-generation blood testing ecosystem.

Cue the music to Queen's classic "We Are The Champions" because we have a winner in the 2023 Austin Inno Madness bracket challenge. After battling through four rounds of voting, Babson Diagnostics has been named champion.

The ViVE conference, powered by HLTH and CHIME, took place March 26-29 against the backdrop of new challenges for healthcare leaders. Nicholas Turos PharmD, vice president of business development with Babson Diagnostics, talks about how his company has reimagined the blood testing experience.

Competition co-hosted by Washington University and American Association for Clinical Chemistry challenges participants to solve real-world clinical laboratory challenges using data science.

Welcome to today’s Biotech Spotlight, a series featuring companies that are creating breakthrough technologies and products. Today, we’re looking at Babson Diagnostics, which is developing a novel blood testing process that requires drops, not vials, of blood.

Making meaningful progress to close the STEM Gap.

The new name of our diagnostic blood testing service is designed around the most important element of testing – the customer.

What do we mean when we say we're a "science-first" company?

Key expertise added as Babson works to commercialize its reimagined blood testing ecosystem.

Better outcomes start with meeting patients where they are.

Media partnership announced in connection with the 2022 National Association of Chain Drug Stores' Total Store Expo.

Claims data underscores need to improve preventative care.

When people think about innovations that can reshape health care, why don’t they usually think about blood testing?

Expanded collaboration agreement to make less invasive blood sample collection more convenient and patient centered.

Babson Diagnostics CEO David Stein details how can patients and providers get the most from virtual care.

Babson awarded accreditation by CAP for meeting the highest standards of quality and patient safety in lab practices.

Healthtech firm prepares for commercial launch of disruptive blood-testing ecosystem.

Babson Diagnostics CEO David Stein shares some ideas about how we as an industry move forward from the Theranos scandal.

With November being National Diabetes Month, it’s a good time to take stock of the toll this disease takes on our country.

Use of COVID-19 testing and vaccination services at community pharmacies demonstrates they can play a bigger role in care delivery.

Babson brings in top talent from the largest and most respected retail and health care services organizations in the country.

The Series B fundraise will accelerate the commercialization of Babson’s disruptive technology that will make routine blood testing easier, more accessible, and less invasive.

We live in a just-in-time world. We only need to pick up our smartphones and within moments we order a car to drive us home. Or book a reservation at a hotel or restaurant.

Babson named one of Fierce Medtech’s elite “Fierce 15" as a promising private company in the global health care industry.

According to the CDC, 70% of today’s medical decisions depend on laboratory test results, and over 14 billion laboratory tests are ordered annually—but primary care clinicians indicate up to 30% of prescribed diagnostic tests are not filled by patients.

Babson announced today it closed $13.7 million in cumulative Series A funding, led by Siemens Healthineers, Prism Ventures, Genesis Merchant Capital, and Lago Consulting Group.

Babson has appointed David Stein, Ph.D., former head of global strategy and innovation at Siemens Healthineers, to chief executive officer. Eric Olson, Babson’s founder and former CEO, will assume the roles of chairman of the board and chief operating officer.

Babson announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA).

Babson announced today it has entered into a collaborative research agreement with Dell Medical School at The University of Texas at Austin (Dell Med) to study the immune response to COVID-19.

Babson announces launch of its first COVID-19 serology test to detect IgG antibodies to SARS-CoV-2 in the bloodstream through a select network of retail and clinical partners in Austin, Texas.

Babson announces it will launch a COVID-19 serology testing service to detect the presence of antibodies to SARS-CoV-2 in the bloodstream.

Babson announces that it has expanded its board of directors to include diagnostics industry leaders David Stein (Director), Dennis Gilbert (Director), and Dave Hickey (Observer).

BD and Babson Diagnostics announce a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies.

Babson has established its Scientific Advisory Board. Drs. Alan Wu, Susan A. Evans, and Robert H. Christenson will join the Babson team as scientific advisors.

Babson named a winner at the Greater Austin Chamber of Commerce’s 2019 Austin A-List Awards, “Austin’s premiere honor for homegrown companies.”

Babson welcomes Mini Kahlon as the newest member of its Board of Directors.

Babson featured in Capital City Innovation's 2018 Annual Review. Capital City Innovation is a 501(c)(3) nonprofit focused on cultivating collaboration and growth in Austin's Innovation District.

Babson secures $3.5 million in Series A financing on October 4 from Prism Ventures, a New York-based advisory and investment firm specializing in life sciences.